Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 4/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16127201 | 0.79 | NAPRT (0.43) | MAPTGAACYP2C19L3MBTL1TSHR | |
| SCHEMBL8292164 | 0.79 | MMP2 (0.39) | MAPTCYP2C19CYP3A4RECQLPTPN1 | |
| SCHEMBL20048670 | 0.76 | TAAR1 (0.50) | GAA | |
| SCHEMBL20048760 | 0.75 | LTA4H (0.36) | MAPTCYP2C19ALDH1A1KDM4E | |
| SCHEMBL21691177 | 0.74 | CTSD (0.41) | CYP2C19TSHRPOLBCYP3A4RECQL | |
| Methylphenylsulfoxide SCHEMBL28161143 | 0.74 | MAPT (0.43) | MAPTGAACYP2C19L3MBTL1TSHR | |
| SCHEMBL20048717 | 0.73 | ALPI (0.36) | MAPTGAAPOLBCYP3A4PMP22 | |
| SCHEMBL20048847 | 0.73 | TAAR1 (0.37) | GAA | |
| SCHEMBL20048759 | 0.73 | LTA4H (0.44) | CYP2C19 | |
| (Phenylsulfinyl)Benzene SCHEMBL8958041 | 0.73 | MAPT (0.44) | MAPTGAAGFERCYP2C19L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6506937-B2 | Used as antiarrhythmics | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-01-14 | — | — | US | claimed |
| CN-1058705-C | Substituted benzene sulfone urea, benzenesulfonyl thiourea its preparation, its application as medicine or diagnostic medicine and drugs containing it | HOECHST AG (DE) | 2000-11-22 | — | — | CN | claimed |
| CN-1137519-A | Substituted benzenesulfonylureas and -thioureas, processes for their preparation, their use for production of pharmaceutical preparations, and pharmaceutical preparations containing them | HOECHST AG (DE) | 1996-12-11 | — | — | CN | claimed |
| CN-1134414-A | Substituted benzene sulfone urea, benzenesulfonyl thiourea its preparation, its application as medicine or diagnostic medicine and drugs containing it | HOECHST AG (DE) | 1996-10-30 | — | — | CN | claimed |
| EP-0006587-B1 | SULFONYL UREAS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-11-11 | — | — | EP | claimed |
| CN-1195524-C | Use of benzenesulfonyl (thio) ureas in combination with beta-receptor blockers for the preparation of a medicament for the treatment and prophylaxis of cardiac vagal dysfunction | AVENTIS PHARMA GMBH (DE) | 2005-04-06 | — | — | CN | disclosed |
| EP-1401419-A1 | BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT OF SEPTIC SHOCK AND SIRS | Aventis Pharma Deutschland GmbH (DE) | 2004-03-31 | — | — | EP | disclosed |
| US-20030083385-A1 | Use of benzenesulfonyl (thioureas or ure as) for treating of septic shock or gene ralized inflammatory syndrome | GERLACH UWE (DE) | 2003-05-01 | — | — | US | disclosed |
| WO-2003000244-A1 | BENZENESULFONYL(THIO)UREAS FOR THE TREATMENT OF SEPTIC SHOCK AND SIRS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-01-03 | — | — | WO | disclosed |
| CN-1319014-A | Use of benzenesulfonyl (thio) ureas for treatment and prophylaxis of dysfunctions of autonomous nervous system and use of benzenesulfonyl(thio) ureas in combination with beta-receptor blockers | AVENTIS PHARMA GMBH (DE) | 2001-10-24 | — | — | CN | disclosed |
| CN-1064041-C | Substituted benzenesulfonylureas and -thioureas, processes for their preparation, their use for production of pharmaceutical preparations, and pharmaceutical preparations containing them | HOECHST AG (DE) | 2001-04-04 | — | — | CN | disclosed |
| CN-1058705-C | Substituted benzene sulfone urea, benzenesulfonyl thiourea its preparation, its application as medicine or diagnostic medicine and drugs containing it | HOECHST AG (DE) | 2000-11-22 | — | — | CN | disclosed |
| CN-1137519-A | Substituted benzenesulfonylureas and -thioureas, processes for their preparation, their use for production of pharmaceutical preparations, and pharmaceutical preparations containing them | HOECHST AG (DE) | 1996-12-11 | — | — | CN | disclosed |
| CN-1134414-A | Substituted benzene sulfone urea, benzenesulfonyl thiourea its preparation, its application as medicine or diagnostic medicine and drugs containing it | HOECHST AG (DE) | 1996-10-30 | — | — | CN | disclosed |
| US-4379785-A | Heterocyclic substituted sulfonyl ureas, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-04-12 | — | — | US | disclosed |
| US-4379153-A | Benzenesulfonyl ureas, and pharmaceutical preparations | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-04-05 | — | — | US | disclosed |
| US-4282239-A | HYPOTENSIVE AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-08-04 | — | — | US | disclosed |
| US-3962244-A | LOWERING OF BLOOD-SUGAR LEVELS | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-06-08 | — | — | US | disclosed |
| US-3932658-A | Composition and method for lower blood sugar containing N-[4-(β-<2-methoxy-5-chloro-benzamido>-ethyl)-benzenesulfonyl]-N'-cyclopentyl-urea | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083385-A1 | Use of benzenesulfonyl (thioureas or ure as) for treating of septic shock or gene ralized inflammatory syndrome | UTS2R, EIF2S1, TST | MAPT 4798/4885GAA 4728/4885GFER 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.